Entheon Biomedical

BioTech Stocks

Company
Last Trade
Change
Volume
Shares Out
Market Cap
US$ 595.40
4.27 0.72
368,286
108.03M
US$ 64.320B
US$ 149.95
7.10 4.97
4.77M
397.76M
US$ 59.640B
US$ 157.50
8.40 5.63
1.32M
243.02M
US$ 38.280B
US$ 22.09
0.63 2.94
409,861
159.84M
US$ 3.530B
US$ 4.42
0.35 8.60
955,481
692.07M
US$ 3.060B
US$ 10.64
-0.01 -0.09
1.97M
281.58M
US$ 3.000B
US$ 2.38
0.00000 0.00000
15.66M
1.09B
US$ 2.590B
US$ 4.55
-0.14 -2.99
1.27M
487.76M
US$ 2.220B
US$ 67.47
1.81 2.76
177,482
25.64M
US$ 1.730B
US$ 9.92
0.84 9.25
2.49M
147.69M
US$ 1.470B
US$ 8.43
0.29 3.56
934,314
159.52M
US$ 1.340B
US$ 6.51
0.08 1.24
1.41M
189.67M
US$ 1.230B
US$ 21.10
1.41 7.16
571,623
51.72M
US$ 1.090B
US$ 26.51
-1.61 -5.73
736,444
40.08M
US$ 1.060B
US$ 22.33
-0.31 -1.37
166,044
43.55M
US$ 972.470M
US$ 37.69
6.55 21.03
100,909
24.10M
US$ 908.330M
US$ 10.30
0.29 2.90
632,353
77.41M
US$ 797.320M
US$ 14.09
0.09 0.64
94,391
55.66M
US$ 784.250M
US$ 3.52
0.28 8.64
1.00M
217.13M
US$ 764.300M
US$ 13.18
0.86 6.98
514,246
48.40M
US$ 637.910M
US$ 1.93
0.08 4.32
3.56M
319.71M
US$ 617.040M
US$ 13.55
-0.01 -0.07
85,204
42.88M
US$ 581.020M
US$ 0.63
0.00200 0.32
789,281
851.56M
US$ 538.190M
US$ 17.49
0.71 4.23
141,400
29.65M
US$ 518.580M
US$ 5.17
0.30 6.16
90,913
94.04M
US$ 486.190M
US$ 10.80
-0.02 -0.18
164,906
42.51M
US$ 459.110M
US$ 6.45
0.09 1.42
605,951
63.01M
US$ 406.410M
US$ 8.08
0.12 1.51
103,805
49.58M
US$ 400.610M
US$ 1.34
-0.04 -2.90
5.83M
289.70M
US$ 388.200M
US$ 13.27
-0.34 -2.50
58,638
26.77M
US$ 355.240M
US$ 10.50
-0.43 -3.93
74,665
33.43M
US$ 351.020M
US$ 3.29
0.08 2.49
196,402
103.00M
US$ 338.870M
US$ 11.15
-0.83 -6.93
134,344
29.17M
US$ 325.250M
US$ 3.33
0.01 0.30
161,405
92.85M
US$ 309.190M
US$ 1.94
0.08 4.30
1.14M
149.59M
US$ 290.200M
US$ 2.31
0.10 4.52
95,744
123.20M
US$ 284.590M
US$ 4.02
0.20 5.24
315,924
70.59M
US$ 283.770M
US$ 12.77
0.45 3.65
58,452
20.94M
US$ 267.400M
US$ 10.63
0.30 2.90
36,652
24.49M
US$ 260.330M
US$ 6.44
0.71 12.39
553,482
39.73M
US$ 255.860M
US$ 7.54
-0.01 -0.13
33,996
32.13M
US$ 242.260M
US$ 10.21
0.28 2.82
33,383
23.63M
US$ 241.260M
US$ 2.15
0.04 1.90
124,756
107.91M
US$ 232.010M
US$ 5.45
-0.18 -3.20
56,475
41.31M
US$ 225.140M
US$ 5.75
0.35 6.48
41,109
39.03M
US$ 224.420M
US$ 9.22
-0.10 -1.07
49,509
23.18M
US$ 213.720M
US$ 0.21
-0.01 -5.59
22.92M
979.90M
US$ 203.620M
US$ 3.72
-0.14 -3.63
7,858
51.29M
US$ 190.540M
US$ 4.81
-0.16 -3.22
65,656
37.60M
US$ 180.860M
US$ 3.63
-0.17 -4.47
143,240
47.85M
US$ 173.700M
US$ 2.82
0.07 2.55
487,374
57.97M
US$ 163.480M
US$ 11.99
0.79 7.05
13,584
12.72M
US$ 152.510M
US$ 4.20
-0.23 -5.19
63,126
36.16M
US$ 151.870M
US$ 2.83
-0.01 -0.35
41,713
47.56M
US$ 134.590M
US$ 5.00
-0.41 -7.58
38,661
26.39M
US$ 131.950M
US$ 0.70
-0.00120 -0.17
736,410
184.20M
US$ 128.720M
US$ 5.49
0.29 5.58
84,786
23.34M
US$ 128.130M
US$ 3.10
0.03 0.98
79,724
39.33M
US$ 121.920M
US$ 1.67
0.00000 0.00000
722,042
68.33M
US$ 114.110M
US$ 0.36
0.00910 2.60
380,670
317.06M
US$ 113.860M
US$ 4.12
-0.09 -2.14
661,805
24.96M
US$ 102.840M
US$ 5.38
-0.18 -3.24
613,940
18.80M
US$ 101.140M
US$ 12.07
0.73 6.44
49,777
8.16M
US$ 98.490M
US$ 7.09
0.11 1.58
28,681
13.35M
US$ 94.650M
US$ 2.30
-2.21 -49.00
3.20M
40.31M
US$ 92.710M
US$ 3.84
0.04 1.05
1,767
23.54M
US$ 90.390M
US$ 1.99
-0.08 -3.67
80,643
43.79M
US$ 87.140M
US$ 3.04
-0.01 -0.33
17,553
28.26M
US$ 85.910M
US$ 1.91
-0.06 -2.80
241,025
43.66M
US$ 83.390M
US$ 1.34
0.02 1.52
31,735
61.93M
US$ 82.990M
US$ 3.16
0.21 6.95
730
25.78M
US$ 81.340M
US$ 1.54
-0.09 -5.52
310,711
50.87M
US$ 78.340M
US$ 1.31
0.00000 0.00000
65,895
59.39M
US$ 77.800M
US$ 2.50
0.14 5.82
13,085
30.40M
US$ 76.000M
US$ 1.72
0.03 1.78
131,707
43.23M
US$ 74.360M
US$ 1.86
0.00000 0.00000
38,480
39.87M
US$ 74.160M
US$ 1.93
-13.36 -87.38
150,836
37.47M
US$ 72.320M
US$ 2.22
-0.05 -2.20
47,732
30.63M
US$ 68.000M
US$ 2.69
0.21 8.47
111,555
25.28M
US$ 68.000M
US$ 1.18
0.02 1.72
18,128
55.57M
US$ 65.570M
US$ 2.55
0.00000 0.00000
21,114
25.65M
US$ 65.410M
US$ 2.65
0.00000 0.00000
84,058
24.46M
US$ 64.820M
US$ 0.16
-0.00500 -2.94
91,700
369.70M
US$ 60.980M
US$ 0.59
0.00450 0.77
424,694
102.20M
US$ 60.250M
US$ 0.72
-0.03 -3.96
48,290
77.33M
US$ 55.700M
US$ 1.52
0.00000 0.00000
0
36.05M
US$ 54.800M
US$ 1.54
0.04 2.35
30,006
35.17M
US$ 53.990M
US$ 1.31
-0.11 -7.75
43,776
41.10M
US$ 53.840M
US$ 2.69
0.05 1.89
291,740
19.09M
US$ 51.350M
US$ 0.05
-0.00200 -4.00
465,380
1.01B
US$ 48.480M
US$ 0.84
-0.03 -3.26
1.04M
53.26M
US$ 44.820M
US$ 1.70
-0.03 -1.73
15,069
25.26M
US$ 42.940M
US$ 2.22
-0.04 -1.77
1,093
18.84M
US$ 41.820M
US$ 3.47
-0.13 -3.61
48,724
11.88M
US$ 41.220M
US$ 2.95
-0.14 -4.53
4,820
13.59M
US$ 40.090M
US$ 1.72
0.11 6.83
32,460
22.84M
US$ 39.280M
US$ 3.32
-0.38 -10.27
36,461
11.40M
US$ 37.850M
US$ 0.31
0.00400 1.29
162,002
116.41M
US$ 36.440M
US$ 2.60
0.00000 0.00000
273,141
13.88M
US$ 36.090M
US$ 1.12
-0.02 -1.75
387,488
29.96M
US$ 33.560M
US$ 0.26
0.00610 2.42
207,227
125.26M
US$ 32.350M
US$ 5.94
0.01 0.17
19,296
5.37M
US$ 31.900M
US$ 0.51
0.00500 0.99
247,766
61.17M
US$ 31.200M
US$ 0.39
0.00000 0.00000
0
78.85M
US$ 30.750M
US$ 0.78
-0.01 -1.27
37,769
38.53M
US$ 30.050M
US$ 1.54
0.00000 0.00000
230
19.17M
US$ 29.520M
US$ 0.30
0.00800 2.76
70,054
97.06M
US$ 28.920M
US$ 0.45
0.05 11.20
200
64.24M
US$ 28.820M
US$ 0.72
-0.01 -1.63
17,962
40.25M
US$ 28.820M
US$ 0.08
0.00270 3.60
5,675
333.40M
US$ 25.910M
US$ 0.67
-0.02 -2.90
3.40M
38.57M
US$ 25.840M
US$ 0.25
0.00500 2.04
123,000
96.89M
US$ 24.220M
US$ 0.31
0.01 4.83
800,753
77.86M
US$ 24.000M
US$ 0.07
0.00500 8.33
64,500
318.30M
US$ 20.690M
US$ 1.14
0.06 5.56
508,331
16.50M
US$ 18.810M
US$ 0.30
-0.09 -22.68
2,000
61.02M
US$ 18.310M
US$ 2.00
0.02 1.01
9,593
9.07M
US$ 18.140M
US$ 1.35
-0.06 -4.26
2,355
12.99M
US$ 17.540M
US$ 2.45
-0.05 -2.00
457
6.96M
US$ 17.050M
US$ 0.07
-0.03 -30.47
8,974
239.53M
US$ 16.890M
US$ 0.26
-0.02 -8.27
964,981
65.53M
US$ 16.710M
US$ 2.76
-0.22 -7.38
58,565
5.95M
US$ 16.420M
US$ 1.09
-0.04 -3.54
6,756
14.75M
US$ 16.080M
US$ 0.66
0.03 4.73
9,098
21.75M
US$ 14.300M
US$ 0.09
0.00000 0.00000
0
132.63M
US$ 11.780M
US$ 0.13
-0.00650 -4.86
100
72.91M
US$ 9.280M
US$ 0.40
-0.00920 -2.25
69,561
21.88M
US$ 8.730M
US$ 0.25
0.00000 0.00000
0
34.19M
US$ 8.540M
US$ 2.61
0.03 1.16
32,696
2.83M
US$ 7.390M
US$ 0.06
0.00000 0.00000
0
121.27M
US$ 7.060M
US$ 0.74
-0.01 -1.33
2.81M
9.51M
US$ 7.040M
US$ 0.02
0.00400 26.32
30,200
364.96M
US$ 7.000M
US$ 0.16
0.00000 0.00000
0
39.04M
US$ 6.260M
US$ 0.45
-0.02 -4.38
260,517
12.66M
US$ 5.700M
US$ 0.09
-0.00800 -8.60
2,345
66.67M
US$ 5.670M
US$ 0.06
0.00000 0.00000
0
88.23M
US$ 5.640M
US$ 0.05
-0.00200 -3.92
25,850
111.14M
US$ 5.450M
US$ 3.00
0.09 3.09
1,153
1.67M
US$ 5.010M
US$ 0.09
0.00000 0.00000
0
51.46M
US$ 4.630M
US$ 0.04
0.00000 0.00000
0
88.94M
US$ 3.380M
US$ 0.03
0.00270 10.80
335,191
97.28M
US$ 2.690M
US$ 0.02
0.00000 0.00000
0
103.35M
US$ 2.170M
US$ 0.00748
0.00000 0.00000
0
120.61M
US$ 902K
US$ 0.01
0.00000 0.00000
0
-
US$ -
US$ 0.07
0.00000 0.00000
0
-
US$ -

BioTech Stock News


Regeneron Pharmaceuticals Completes Purchase of Sanofi's Stake in Libtayo®

Company provides anticipated impact to second quarter 2022 financial results due to recently completed business development transactions Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that it has completed the acquisition of Sanofi's stake in Libtayo® (cemiplimab), providing Regeneron with exclusive worldwide development, commercialization, and manufacturing rights to the medicine... Read more


Aequus Pharmaceuticals Provides General Update and Reports Record 2021 Financial Results

Also reports Financial Results for the 3 months ended March 31, 2022 Aequus Pharmaceuticals Inc. (TSX-V: AQS, OTCQB: AQSZF) (“Aequus” or the “Company”), a specialty pharmaceutical company with a sales force that currently markets third party or exclusively licensed products for which the Company receives revenues from direct product sales and profit share arrangements, today reported financial... Read more


Biomea Fusion Selected for Two Oral Presentations at the European Association for the Study of Diabetes Annual Meeting Describing BMF-219’s Potential as a Novel, Oral, Long-Acting, Acute Treatment for...

Biomea to present two oral abstracts across multiple animal models highlighting the ability of BMF-219, a covalent menin inhibitor, to significantly lower HbA1C (approximately two-fold greater reduction than active control, liraglutide) and to increase beta cell function. BMF-219 showed prolonged glycemic control in two standard diabetes animal models, the Zucker Diabetic Fatty (ZDF) and Stre... Read more


Centessa Pharmaceuticals Announces Appointment of Dr. Mathias Hukkelhoven to its Board of Directors

Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company with a Research & Development (“R&D”) innovation engine that aims to discover, develop and ultimately deliver impactful medicines to patients, today announced the appointment of Mathias Hukkelhoven, Ph.D., formerly Senior Vice President, Global Regulatory, Safety & Biometrics at Bristol... Read more


BioCorRx Announces First Subject Dosed in Phase I Clinical Trial of BICX104, an Implantable Naltrexone Pellet for the Treatment of Opioid Use Disorder

BioCorRx Inc. (OTCQB: BICX) (the “Company”), a developer and provider of innovative treatment programs for substance abuse and related disorders, today announced that the first subject has been dosed in the Phase I clinical trial of BICX104, an implantable biodegradable naltrexone pellet for the treatment of opioid use disorder (OUD), which is being developed under BioCorRx Pharmaceuticals, Inc.,... Read more


Talaris Therapeutics Provides FREEDOM-1 Phase 3 Clinical Update

All three FREEDOM-1 patients treated with FCR001 who are more than 12 months post-transplant have been successfully weaned off chronic anti-rejection drugs All FREEDOM-1 patients who received FCR001 at least three months prior to the data cutoff date have achieved and maintained >50% T-cell chimerism, a potential biomarker predictive of achieving tolerance Conference call scheduled for today... Read more


Pfizer and BioNTech Announce New Agreement with U.S. Government to Provide Additional Doses of COVID-19 Vaccine

105 million 30 µg, 10 µg and 3 µg doses to be delivered into Q4 2022, with an option for the U.S. Government to purchase up to 195 million additional doses Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced a new vaccine supply agreement with the U.S. government to support the continued fight against COVID-19. Under the agreement, the U.S. government will receive 105 million... Read more


Lexicon Pharmaceuticals Announces Positive Top-Line Results From Phase 2 Proof-Of-Concept Study Of LX9211 In Painful Diabetic Neuropathy

Study Supports Translation of Potential New Mechanism of Action for Neuropathic Pain and Advancement of LX9211 Development in Painful Diabetic Neuropathy Conference Call and Webcast at 8:00 a.m. Eastern Time June 30, 2022 Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced top-line results of RELIEF-DPN-1, its Phase 2 proof-of-concept study of LX9211 in painful diabetic neuropathy.... Read more


Bionano Genomics Announces Issuance of a U.S. Patent for Analysis of Small Nucleic Acid Fragments in Nanochannel Arrays

Bionano Genomics, Inc. (Nasdaq: BNGO), today announced that the United States Patent and Trademark Office issued US Patent No.11,359,244 on June 14, 2022. The patent, titled “CHARACTERIZATION OF MOLECULES IN NANOFLUIDICS” claims methods for the analysis of small nucleic acid fragments in nanochannel arrays, which Bionano has traditionally used to analyze ultra-high molecular weight... Read more


Regeneron Pharmaceuticals: EYLEA® (aflibercept) Injection sBLA for Every 16-week Dosing Regimen in Patients with Diabetic Retinopathy Accepted for FDA Review

If approved, extended regimen would provide a longer treatment interval and additional dosing flexibility, alongside approved every 4- and 8-week dosing regimens Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced the U.S. Food and Drug Administration (FDA) has accepted for review the EYLEA® (aflibercept) Injection supplemental Biologics License Application (sBLA)... Read more


Lilly to Supply an Additional 150,000 Doses of AbCellera-Discovered Antibody, Bebtelovimab, to the U.S. Government in Ongoing Effort to Provide COVID-19 Treatment Options

AbCellera (Nasdaq: ABCL) today announced that Eli Lilly and Company (Lilly) has entered into a modified purchase agreement with the U.S. government to supply an additional 150,000 doses of bebtelovimab, the second antibody developed through AbCellera’s collaboration with Lilly, for approximately $275 million. The existing U.S. government supply of bebtelovimab, including the new purchase, is expected... Read more


Jaguar Health Enters Exclusive Crofelemer License and Commercialization Agreement with SynWorld Technologies for Canalevia for Treatment of Diarrhea in Dogs in China

License fees of $5.0 million, and up to $5.0 million in unregistered equity infusion, over next 24 months Service agreement of up to $5.0 million payable in unregistered Jaguar stock to SynWorld to support approval of crofelemer in China, providing Jaguar Health with up to 80% of profits Jaguar Health, Inc. (NASDAQ:JAGX) (Jaguar) today announced that the company has entered an exclusive license... Read more


Elite Pharmaceuticals Receives FDA Approval for Generic Sabril

Elite Pharmaceuticals, Inc. ("Elite" or the "Company") (OTCQB:ELTP), a specialty pharmaceutical company developing niche generic products, today announced that it received approval from the US Food and Drug Administration (FDA) for an Abbreviated New Drug Application (ANDA) for a generic version of Sabril® (Vigabatrin USP) 500 mg powder for solution packet. Vigabatrin is an antiepileptic drug indicated... Read more


Tryp Therapeutics Strengthens IP Portfolio with Provisional Patent Application for Binge Eating Disorder Treatment

Biotech Company Strengthens Strategic Intellectual Property Protection of Targeted Indication Tryp Therapeutics, Inc. (CSE: TRYP) (OTCQB: TRYPF) ("Tryp" or the "Company"), a clinical-stage biotechnology company focused on developing psilocybin-based compounds for diseases with unmet medical needs, announced today the filing of a new provisional patent for the use of psilocybin for the treatment... Read more


Humacyte Announces JAMA Surgery Publication Highlighting Potential of Human Acellular Vessel™ to Expand Vascular Trauma Reconstruction and Bypass Treatment Options

HAV implanted in nearly 500 patients with more than 1,000 patient-years of follow up to date, for treatment of peripheral arterial disease, arteriovenous access for hemodialysis, and trauma Immediately-available HAV, if approved, would represent significant and innovative advancements for vascular repair and replacement conduits Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology... Read more


Palisade Bio Initiates Phase 3 Study of LB1148 in Lead Indication for Postoperative Return of Bowel Function

Completion of enrollment for Phase 3 study targeted within 18-24 months In multiple clinical studies, LB1148 has demonstrated statistically significant acceleration in the time to the return of normal GI function, and has the potential to prevent damage to GI tissues and shorten the duration of costly post-surgery hospital stays Phase 3 study design utilizes same dosing protocol and same primary... Read more


Odyssey Group Completes Safety Evaluation of Cohort II for Concussion Drug

Odyssey Health, Inc. (OTC Pink: ODYY), f/k/a Odyssey Group International, Inc., a company focused on developing unique, life-saving medical products, today announced positive safety findings from Cohort II of their Phase I clinical trial. Odyssey’s trial involves administering PRV-002, the Company’s novel drug to treat concussion, to healthy human subjects. Data from Cohort II indicates that... Read more


Appili Therapeutics Reports Fiscal Year 2022 Financial and Operational Results

Appili Therapeutics Inc. (TSX: APLI; OTCQX: APLIF) (the “Company” or “Appili”), a biopharmaceutical company focused on drug development for infectious diseases and biodefense, today announced its financial and operational results for the fiscal year ended March 31, 2022, and provided an update on the Company’s strategy for fiscal 2023. All figures are stated in Canadian dollars unless otherwise... Read more


VectivBio Announces Closing of $54 Million Aggregate Financing

VectivBio Holding AG (“VectivBio”) (Nasdaq: VECT), a clinical-stage biopharmaceutical company pioneering novel transformational treatments for severe rare conditions, announces it has closed each of its previously announced public offering of 6,467,688 ordinary shares, including the sale to the underwriters of 752,688 ordinary shares sold pursuant to the partial exercise of the underwriters’... Read more


Adagene Announces Authorization of Share Repurchase Program up to US$10 Million

Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a company transforming the discovery and development of novel antibody-based therapies, today announced that its board of directors has authorized a share repurchase program under which, Adagene may repurchase up to US$10 million of its ordinary shares in the form of American depositary shares, subject to the relevant rules under the Securities Exchange... Read more


Aytu BioPharma Announces the Appointment of Vivian Liu to the Company's Board of Directors

Aytu BioPharma, Inc. (NASDAQ:AYTU), a pharmaceutical company focused on developing and commercializing novel therapeutics, today announced the appointment of Vivian Liu to the company's board of directors, effective July 1, 2022. Ms. Liu will serve as an independent director and as a member of the Nominating & Corporate Governance Committee. "I'm thrilled to welcome Vivian to Aytu's board of... Read more


Icosavax Announces Positive Topline Interim Phase 1/1b Results for VLP Vaccine Candidate IVX-121 Against RSV

- IVX-121 demonstrated robust immunologic response to RSV, with comparable Geometric Mean Titer (GMT) levels achieved at Day 28 in both young and older adult groups - - IVX-121 was generally well tolerated with no vaccine-related SAEs - - Provides initial indication of a differentiated VLP platform technology - - Icosavax plans to file an IND submission and initiate a Phase 1 trial for IVX-A12,... Read more


Certara Introduces New Simcyp™ Discovery Simulator for Early-Stage and Translational Drug Development

Certara (Nasdaq: CERT), a global leader in biosimulation, today announced the release of Simcyp Discovery Simulator, a new software designed for scientists working in small molecule drug discovery and translational research. Derived from the industry-leading Simcyp Simulator, Simcyp Discovery increases confidence in early-stage development decisions using physiologically-based pharmacokinetic (PBPK)... Read more


Zomedica Announces Designation of PulseVet(R) System as the Official Shock Wave Therapy Supplier of the United States Equestrian Team

Zomedica Corp. (NYSE American:ZOM) ("Zomedica" or the "Company"), a veterinary health company offering diagnostic and therapeutic products for equine and companion animals, is honored to announce that the United States Equestrian Federation (USEF) has named PulseVet as the Official Shock Wave Therapy Supplier of US Equestrian Team Veterinarians. "The USEF is pleased to partner with a company that... Read more


Roivant Sciences Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2022 and Provides Business Update

Potential blockbuster VTAMA® (tapinarof) approved by FDA for the treatment of plaque psoriasis at end of May 2022 is the first topical novel chemical entity launched for plaque psoriasis in 25 years; product and samples are now available across the US, a robust patient support program is in place and a 100+ person commercial organization is fully deployed to target 4 million potential annual topical... Read more


Roivant Sciences and Pfizer Unveil Priovant Therapeutics and Ongoing Registrational Studies for Oral Brepocitinib in Dermatomyositis and Lupus

Roivant Sciences and Pfizer today announced the unveiling of Priovant Therapeutics, dedicated to developing and commercializing novel therapies for autoimmune diseases with the greatest morbidity and mortality. Priovant was established in September 2021 through a transaction between Roivant (Nasdaq: ROIV) and Pfizer (NYSE: PFE), in which Pfizer licensed oral and topical brepocitinib’s global development... Read more


Healthy Extracts Enters Retail Marketplace, Launching Brain Health Products in Over 160 Natural Grocers® Stores Nationwide

Healthy_Extracts' (OTCQB: HYEX) clinically proven, plant-based products for brain health are now shipping to more than 160 Natural Grocers® stores nationwide. Natural Grocers is the nation's largest family-operated organic and natural grocery retailer. The retailer also provides extensive free science-based nutrition education programs that help consumers make informed nutritional health... Read more


JanOne Announces an Improved Formulation of JAN101

Recent Developments at the University of Iowa have Resulted in an Improved Formulation of JAN101 JanOne Inc. ("JanOne") (Nasdaq: JAN), a company that focuses on the development of drugs with non-addictive, pain-relieving properties, announced today that work has been completed by Dr. Maureen Donovan at the University of Iowa that will allow for an improved formulation of JAN101. JAN101 (formerly... Read more


Decibel Therapeutics Reports Positive Data from Interim Analysis of Ongoing Phase 1b Clinical Trial of DB-020 in Patients Receiving Cisplatin Chemotherapy

87% of patients who experienced ototoxicity in their placebo-treated ear were protected from ototoxicity in their DB-020-treated ear  Data support continued development of DB-020 as a potential therapy to protect against hearing loss in patients receiving cisplatin chemotherapy for cancer  Management will review results during a webcast today at 8:00 a.m. EDT  Decibel Therapeutics... Read more


ZOMEDICA

Read more

COPYRIGHT ©2022 GREEN STOCK NEWS